Inter- and intra-tumor heterogeneity of metastatic prostate cancer determined by digital spatial gene expression profiling

被引:156
作者
Brady, Lauren [1 ]
Kriner, Michelle [2 ]
Coleman, Ilsa [1 ]
Morrissey, Colm [3 ]
Roudier, Martine [3 ]
True, Lawrence D. [3 ]
Gulati, Roman [1 ]
Plymate, Stephen R. [3 ,4 ]
Zhou, Zoey [2 ]
Birditt, Brian [2 ]
Meredith, Rhonda [2 ]
Geiss, Gary [2 ]
Hoang, Margaret [2 ]
Beechem, Joseph [2 ]
Nelson, Peter S. [1 ,3 ]
机构
[1] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA
[2] NanoString Technol Inc, Seattle, WA USA
[3] Univ Washington, Seattle, WA 98195 USA
[4] VAPSHCS GRECC, Seattle, WA USA
关键词
ANDROGEN RECEPTOR; TARGETING B7-H3; DOUBLE-BLIND; ADENOCARCINOMA; RESISTANCE; PROGRAM; RNA; IPILIMUMAB; DIVERSITY; CARCINOMA;
D O I
10.1038/s41467-021-21615-4
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Metastatic prostate cancer (mPC) comprises a spectrum of diverse phenotypes. However, the extent of inter- and intra-tumor heterogeneity is not established. Here we use digital spatial profiling (DSP) technology to quantitate transcript and protein abundance in spatially-distinct regions of mPCs. By assessing multiple discrete areas across multiple metastases, we find a high level of intra-patient homogeneity with respect to tumor phenotype. However, there are notable exceptions including tumors comprised of regions with high and low androgen receptor (AR) and neuroendocrine activity. While the vast majority of metastases examined are devoid of significant inflammatory infiltrates and lack PD1, PD-L1 and CTLA4, the B7-H3/CD276 immune checkpoint protein is highly expressed, particularly in mPCs with high AR activity. Our results demonstrate the utility of DSP for accurately classifying tumor phenotype, assessing tumor heterogeneity, and identifying aspects of tumor biology involving the immunological composition of metastases. The inter- and intra-tumor heterogeneity of metastatic prostate cancer (mPC) is underexplored. Here the authors use Digital Spatial Profiling to study gene and protein expression heterogeneity in 27 mPC patients, finding variation in associated pathways and potential immunotherapy targets.
引用
收藏
页数:16
相关论文
共 72 条
  • [1] Genomic correlates of clinical outcome in advanced prostate cancer
    Abida, Wassim
    Cyrta, Joanna
    Heller, Glenn
    Prandi, Davide
    Armenia, Joshua
    Coleman, Ilsa
    Cieslik, Marcin
    Benelli, Matteo
    Robinson, Dan
    Van Allen, Eliezer M.
    Sboner, Andrea
    Fedrizzi, Tarcisio
    Mosquera, Juan Miguel
    Robinson, Brian D.
    De Sarkar, Navonil
    Kunju, Lakshmi P.
    Tomlins, Scott
    Wu, Yi Mi
    Rodrigues, Daniel Nava
    Loda, Massimo
    Gopalan, Anuradha
    Reuter, Victor E.
    Pritchard, Colin C.
    Mateo, Joaquin
    Bianchini, Diletta
    Miranda, Susana
    Carreira, Suzanne
    Rescigno, Pasquale
    Filipenko, Julie
    Vinson, Jacob
    Montgomery, Robert B.
    Beltran, Himisha
    Heath, Elisabeth I.
    Scher, Howard I.
    Kantoff, Philip W.
    Taplin, Mary-Ellen
    Schultz, Nikolaus
    deBono, Johann S.
    Demichelis, Francesca
    Nelson, Peter S.
    Rubin, Mark A.
    Chinnaiyan, Arul M.
    Sawyers, Charles L.
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2019, 116 (23) : 11428 - 11436
  • [2] Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study
    Antonarakis, Emmanuel S.
    Piulats, Josep M.
    Gross-Goupil, Marine
    Goh, Jeffrey
    Ojamaa, Kristiina
    Hoimes, Christopher J.
    Vaishampayan, Ulka
    Berger, Ranaan
    Sezer, Ahmet
    Alanko, Tuomo
    de Wit, Ronald
    Li, Chunde
    Omlin, Aurelius
    Procopio, Giuseppe
    Fukasawa, Satoshi
    Tabata, Ken-ichi
    Park, Se Hoon
    Feyerabend, Susan
    Drake, Charles G.
    Wu, Haiyan
    Qiu, Ping
    Kim, Jeri
    Poehlein, Christian
    de Bono, Johann Sebastian
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (05)
  • [3] AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
    Antonarakis, Emmanuel S.
    Lu, Changxue
    Wang, Hao
    Luber, Brandon
    Nakazawa, Mary
    Roeser, Jeffrey C.
    Chen, Yan
    Mohammad, Tabrez A.
    Chen, Yidong
    Fedor, Helen L.
    Lotan, Tamara L.
    Zheng, Qizhi
    De Marzo, Angelo M.
    Isaacs, John T.
    Isaacs, William B.
    Nadal, Rosa
    Paller, Channing J.
    Denmeade, Samuel R.
    Carducci, Michael A.
    Eisenberger, Mario A.
    Luo, Jun
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (11) : 1028 - 1038
  • [4] Ayala G, 2003, CLIN CANCER RES, V9, P4792
  • [5] Single-Cell Analysis Identifies LY6D as a Marker Linking Castration-Resistant Prostate Luminal Cells to Prostate Progenitors and Cancer
    Barros-Silva, Joao D.
    Linn, Douglas E.
    Steiner, Ivana
    Guo, Guoji
    Ali, Adnan
    Pakula, Hubert
    Ashton, Garry
    Peset, Isabel
    Brown, Michael
    Clarke, Noel W.
    Bronson, Roderick T.
    Yuan, Guo-Cheng
    Orkin, Stuart H.
    Li, Zhe
    Baena, Esther
    [J]. CELL REPORTS, 2018, 25 (12): : 3504 - +
  • [6] Beechem JM, 2020, METHODS MOL BIOL, V2055, P563, DOI 10.1007/978-1-4939-9773-2_25
  • [7] Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer
    Beer, Tomasz M.
    Kwon, Eugene D.
    Drake, Charles G.
    Fizazi, Karim
    Logothetis, Christopher
    Gravis, Gwenaelle
    Ganju, Vinod
    Polikoff, Jonathan
    Saad, Fred
    Humanski, Piotr
    Piulats, Josep M.
    Gonzalez Mella, Pablo
    Ng, Siobhan S.
    Jaeger, Dirk
    Parnis, Francis X.
    Franke, Fabio A.
    Puente, Javier
    Carvajal, Roman
    Sengelov, Lisa
    McHenry, M. Brent
    Varma, Arvind
    van den Eertwegh, Alfonsus J.
    Gerritsen, Winald
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (01) : 40 - +
  • [8] The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance
    Beltran, Himisha
    Hruszkewycz, Andrew
    Scher, Howard I.
    Hildesheim, Jeffrey
    Isaacs, Jennifer
    Yu, Evan Y.
    Kelly, Kathleen
    Lin, Daniel
    Dicker, Adam
    Arnold, Julia
    Hecht, Toby
    Wicha, Max
    Sears, Rosalie
    Rowley, David
    White, Richard
    Gulley, James L.
    Lee, John
    Meco, Maria Diaz
    Small, Eric J.
    Shen, Michael
    Knudsen, Karen
    Goodrich, David W.
    Lotan, Tamara
    Zoubeidi, Amina
    Sawyers, Charles L.
    Rudin, Charles M.
    Loda, Massimo
    Thompson, Timothy
    Rubin, Mark A.
    Tawab-Amiri, Abdul
    Dahut, William
    Nelson, Peter S.
    [J]. CLINICAL CANCER RESEARCH, 2019, 25 (23) : 6916 - 6924
  • [9] Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer
    Beltran, Himisha
    Prandi, Davide
    Mosquera, Juan Miguel
    Benelli, Matteo
    Puca, Loredana
    Cyrta, Joanna
    Marotz, Clarisse
    Giannopoulou, Eugenia
    Chakravarthi, Balabhadrapatruni V. S. K.
    Varambally, Sooryanarayana
    Tomlins, Scott A.
    Nanus, David M.
    Tagawa, Scott T.
    Van Allen, Eliezer M.
    Elemento, Olivier
    Sboner, Andrea
    Garraway, Levi A.
    Rubin, Mark A.
    Demichelis, Francesca
    [J]. NATURE MEDICINE, 2016, 22 (03) : 298 - 305
  • [10] Correlation of B7-H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysis
    Benzon, B.
    Zhao, S. G.
    Haffner, M. C.
    Takhar, M.
    Erho, N.
    Yousefi, K.
    Hurley, P.
    Bishop, J. L.
    Tosoian, J.
    Ghabili, K.
    Alshalalfa, M.
    Glavaris, S.
    Simons, B. W.
    Tran, P.
    Davicioni, E.
    Karnes, R. J.
    Boudadi, K.
    Antonarakis, E. S.
    Schaeffer, E. M.
    Drake, C. G.
    Feng, F.
    Ross, A. E.
    [J]. PROSTATE CANCER AND PROSTATIC DISEASES, 2017, 20 (01) : 28 - 35